Is Medical Cannabis Available on the NHS?

Medical Cannabis on the NHS: The Reality

Since medical cannabis was legalised in November 2018, the question of NHS availability has been a source of significant confusion and frustration for UK patients. The short answer: NHS access is extremely limited, and almost all UK medical cannabis prescriptions are issued privately.

What the NHS Currently Prescribes

The NHS prescribes cannabis-based medicines only in three specific situations:

1. Epidyolex (CBD) for Epilepsy

Epidyolex is a pharmaceutical-grade CBD (cannabidiol) oral solution licensed for two rare, severe epilepsy syndromes: Dravet syndrome and Lennox-Gastaut syndrome. It is available on the NHS following NICE approval in 2019. This is a pure CBD medicine with no THC.

2. Sativex for MS Spasticity

Sativex (nabiximols) is a 1:1 THC:CBD oromucosal spray used for muscle spasticity in multiple sclerosis. Despite being licensed and recommended by NICE in 2019, NHS availability has been very limited in practice. Most MS patients still cannot access it on the NHS due to commissioning gaps between NICE guidance and NHS England implementation.

3. Nabilone for Chemotherapy Nausea

Nabilone is a synthetic THC analogue available on the NHS for nausea and vomiting caused by chemotherapy. It has been available for several decades and predates the 2018 legalisation.

Why Can I Not Get Cannabis on the NHS for Pain, Anxiety, or PTSD?

The NHS follows NICE guidelines, which require robust clinical trial evidence before recommending treatments. Despite the 2018 legalisation, NICE has found insufficient evidence from randomised controlled trials to recommend cannabis-based medicines for most conditions outside the three above. This is partly a chicken-and-egg problem: evidence takes time to accumulate, and clinical trials require access to standardised products.

Critics point out that while the NHS waits for RCT evidence, hundreds of thousands of patients are self-medicating with illicit cannabis, which poses significantly higher risks than pharmaceutical-grade prescribed medicines.

The Project Twenty21 and ACCESS Programme

Project Twenty21 (coordinated by Drug Science) ran from 2019–2022 and enrolled over 3,000 patients in a real-world evidence collection programme. It provided reduced-cost medical cannabis access and generated significant evidence on safety and efficacy for conditions including chronic pain, PTSD, anxiety, insomnia, and MS.

The ACCESS programme is the successor, continuing to collect evidence and advocating for NHS integration. If you cannot afford private prescriptions, ask your clinic about reduced-cost research programmes.

Will the NHS Start Prescribing More Widely?

There are cautious signs of progress. Several NHS trusts are participating in research programmes, and there is increasing political pressure to improve access. However, mainstream NHS prescribing for conditions like chronic pain and PTSD is unlikely before 2027–2030 at the earliest, based on current evidence timelines.

What to Do If You Cannot Afford Private Prescriptions

1. Use a low-cost clinic: Mamedica charges no consultation or repeat fees. Your only cost is the medicine itself.
2. Compare medicine prices: LeafMe shows you the cheapest source for your specific prescription — savings of £30–£80/month are common.
3. Choose CBD-dominant products: Lower-THC, higher-CBD products are often 40–60% cheaper and still effective for anxiety, inflammation, and mild pain.
4. Ask about hardship funds: Some clinics have discretionary schemes for patients in financial difficulty.
5. Check research programme eligibility: Some university hospitals offer subsidised or free access through research programmes.

Making the Case to Your GP

While GPs cannot currently prescribe medical cannabis, they can refer you to the right specialist and write supporting letters. A GP's endorsement can strengthen your case with a private clinic. Inform your GP of your medical cannabis use — they remain responsible for your overall care and may be aware of local research programmes or NHS pathway development in your area.